Quarterly report [Sections 13 or 15(d)]

SIGNIFICANT ACCOUNTING POLICIES (Tables)

v3.25.3
SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2025
SIGNIFICANT ACCOUNTING POLICIES  
Schedule of net sales

 

 

Three Months Ended

September 30

 

 

 

2025

 

 

2024

 

Sales/access fees

 

$ -

 

 

$ -

 

Distribution rights income

 

 

-

 

 

 

-

 

Supply and distribution sales

 

 

635,224

 

 

 

-

 

Net sales

 

$ 635,224

 

 

$ -

 

 

 

Nine Months Ended

September 30

 

 

 

2025

 

 

2024

 

Sales/access fees

 

$

1,790

 

 

$

2,205

 

Distribution rights income

 

 

-

 

 

 

4,045

 

Membership/program fees

 

 

-

 

 

 

1,415

 

Supply and distribution sales

 

 

946,572

 

 

 

-

 

Net sales

 

948,362

 

 

$

7,665

 

Schedule of Inventory

 

 

September 30,

2025

 

 

December 31,

2024

 

Raw materials

 

$

-

 

 

$

-

 

Work-in-progress

 

 

-

 

 

 

-

 

Finished goods

 

 

155,367

 

 

 

-

 

 

 

$

155,367

 

 

$

-

 

Schedule of antidilutive securities

 

 

Three months ended

September 30,

 

 

Nine months ended

September 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Net loss Attributable to BioCorRX inc.

 

$ (1,917,873 )

 

$ (1,487,387 )

 

$ (3,992,701 )

 

$ (3,941,509 )

Net loss per common share, basic and diluted

 

$ (0.11 )

 

$ (0.14 )

 

$ (0.24 )

 

$ (0.41 )

Weighted average number of common shares outstanding, basic and diluted

 

 

18,162,783

 

 

 

10,908,291

 

 

 

16,901,306

 

 

 

9,712,939